On May 10th local time, the US Congress released a revised version of the Biosafety Act, and the US House of Representatives committee is expected to decide next week whether to proceed with the bill. The revised bill will restrict US entities from conducting business with certain Chinese biotechnology companies, including WuXi AppTec and BGI, and explicitly require US companies to end their cooperation with these companies before January 2032, which extends the buffer time for companies to seek new partners. Industry insiders believe that 8 years is enough for relevant companies to adapt, and the implementation of this greatest uncertainty may have a positive impact on related companies.
On May 10th local time, the US Congress released a revised version of the Biosafety Act, and the US House of Representatives committee is expected to decide next week whether to proceed with the bill. The revised bill will restrict US entities from conducting business with certain Chinese biotechnology companies, including WuXi AppTec and BGI, and explicitly require US companies to end their cooperation with these companies before January 2032, which extends the buffer time for companies to seek new partners. Industry insiders believe that 8 years is enough for relevant companies to adapt, and the implementation of this greatest uncertainty may have a positive impact on related companies.